A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product—protein or polypeptide.
Market Analysis and Insights: Global Gene Engineered Subunit Vaccine Market
The global Gene Engineered Subunit Vaccine market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Engineered Subunit Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Engineered Subunit Vaccine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Engineered Subunit Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Engineered Subunit Vaccine market.
Gene Engineered Subunit Vaccine Breakdown Data by Type
Therapeutic Gene Engineered Subunit Vaccine
Preventative Gene Engineered Subunit Vaccine
Gene Engineered Subunit Vaccine Breakdown Data by Application
Human Use
Veterinary Use
Based on regional and country-level analysis, the Gene Engineered Subunit Vaccine market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Gene Engineered Subunit Vaccine market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
The following players are covered in this report:
Merck
GSK
Tiantan
Pulike
Greffex
CureVac
Yebio
Sanofi Pasteur SA
Virbac
Pfizer Inc.
Walvax Biotechnology
Kontec
Market Analysis and Insights: Global Gene Engineered Subunit Vaccine Market
The global Gene Engineered Subunit Vaccine market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Engineered Subunit Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Engineered Subunit Vaccine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Engineered Subunit Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Engineered Subunit Vaccine market.
Gene Engineered Subunit Vaccine Breakdown Data by Type
Therapeutic Gene Engineered Subunit Vaccine
Preventative Gene Engineered Subunit Vaccine
Gene Engineered Subunit Vaccine Breakdown Data by Application
Human Use
Veterinary Use
Based on regional and country-level analysis, the Gene Engineered Subunit Vaccine market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Gene Engineered Subunit Vaccine market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
The following players are covered in this report:
Merck
GSK
Tiantan
Pulike
Greffex
CureVac
Yebio
Sanofi Pasteur SA
Virbac
Pfizer Inc.
Walvax Biotechnology
Kontec
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Engineered Subunit Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Therapeutic Gene Engineered Subunit Vaccine
1.2.3 Preventative Gene Engineered Subunit Vaccine
1.3 Market by Application
1.3.1 Global Gene Engineered Subunit Vaccine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Human Use
1.3.3 Veterinary Use
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Gene Engineered Subunit Vaccine Market Perspective (2016-2027)
2.2 Gene Engineered Subunit Vaccine Growth Trends by Regions
2.2.1 Gene Engineered Subunit Vaccine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Gene Engineered Subunit Vaccine Historic Market Share by Regions (2016-2021)
2.2.3 Gene Engineered Subunit Vaccine Forecasted Market Size by Regions (2022-2027)
2.3 Gene Engineered Subunit Vaccine Industry Dynamic
2.3.1 Gene Engineered Subunit Vaccine Market Trends
2.3.2 Gene Engineered Subunit Vaccine Market Drivers
2.3.3 Gene Engineered Subunit Vaccine Market Challenges
2.3.4 Gene Engineered Subunit Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Engineered Subunit Vaccine Players by Revenue
3.1.1 Global Top Gene Engineered Subunit Vaccine Players by Revenue (2016-2021)
3.1.2 Global Gene Engineered Subunit Vaccine Revenue Market Share by Players (2016-2021)
3.2 Global Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Gene Engineered Subunit Vaccine Revenue
3.4 Global Gene Engineered Subunit Vaccine Market Concentration Ratio
3.4.1 Global Gene Engineered Subunit Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Engineered Subunit Vaccine Revenue in 2020
3.5 Gene Engineered Subunit Vaccine Key Players Head office and Area Served
3.6 Key Players Gene Engineered Subunit Vaccine Product Solution and Service
3.7 Date of Enter into Gene Engineered Subunit Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Engineered Subunit Vaccine Breakdown Data by Type
4.1 Global Gene Engineered Subunit Vaccine Historic Market Size by Type (2016-2021)
4.2 Global Gene Engineered Subunit Vaccine Forecasted Market Size by Type (2022-2027)
5 Gene Engineered Subunit Vaccine Breakdown Data by Application
5.1 Global Gene Engineered Subunit Vaccine Historic Market Size by Application (2016-2021)
5.2 Global Gene Engineered Subunit Vaccine Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Gene Engineered Subunit Vaccine Market Size (2016-2027)
6.2 North America Gene Engineered Subunit Vaccine Market Size by Type
6.2.1 North America Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
6.2.2 North America Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
6.2.3 North America Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
6.3 North America Gene Engineered Subunit Vaccine Market Size by Application
6.3.1 North America Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
6.3.2 North America Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
6.3.3 North America Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
6.4 North America Gene Engineered Subunit Vaccine Market Size by Country
6.4.1 North America Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
6.4.2 North America Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Gene Engineered Subunit Vaccine Market Size (2016-2027)
7.2 Europe Gene Engineered Subunit Vaccine Market Size by Type
7.2.1 Europe Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
7.2.2 Europe Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
7.2.3 Europe Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
7.3 Europe Gene Engineered Subunit Vaccine Market Size by Application
7.3.1 Europe Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
7.3.2 Europe Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
7.3.3 Europe Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
7.4 Europe Gene Engineered Subunit Vaccine Market Size by Country
7.4.1 Europe Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
7.4.2 Europe Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size (2016-2027)
8.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type
8.2.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
8.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application
8.3.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
8.4 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region
8.4.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Gene Engineered Subunit Vaccine Market Size (2016-2027)
9.2 Latin America Gene Engineered Subunit Vaccine Market Size by Type
9.2.1 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
9.2.2 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
9.2.3 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
9.3 Latin America Gene Engineered Subunit Vaccine Market Size by Application
9.3.1 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
9.3.2 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
9.3.3 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
9.4 Latin America Gene Engineered Subunit Vaccine Market Size by Country
9.4.1 Latin America Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
9.4.2 Latin America Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size (2016-2027)
10.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type
10.2.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
10.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application
10.3.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
10.4 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country
10.4.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Gene Engineered Subunit Vaccine Introduction
11.1.4 Merck Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.1.5 Merck Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Gene Engineered Subunit Vaccine Introduction
11.2.4 GSK Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.2.5 GSK Recent Development
11.3 Tiantan
11.3.1 Tiantan Company Details
11.3.2 Tiantan Business Overview
11.3.3 Tiantan Gene Engineered Subunit Vaccine Introduction
11.3.4 Tiantan Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.3.5 Tiantan Recent Development
11.4 Pulike
11.4.1 Pulike Company Details
11.4.2 Pulike Business Overview
11.4.3 Pulike Gene Engineered Subunit Vaccine Introduction
11.4.4 Pulike Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.4.5 Pulike Recent Development
11.5 Greffex
11.5.1 Greffex Company Details
11.5.2 Greffex Business Overview
11.5.3 Greffex Gene Engineered Subunit Vaccine Introduction
11.5.4 Greffex Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.5.5 Greffex Recent Development
11.6 CureVac
11.6.1 CureVac Company Details
11.6.2 CureVac Business Overview
11.6.3 CureVac Gene Engineered Subunit Vaccine Introduction
11.6.4 CureVac Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.6.5 CureVac Recent Development
11.7 Yebio
11.7.1 Yebio Company Details
11.7.2 Yebio Business Overview
11.7.3 Yebio Gene Engineered Subunit Vaccine Introduction
11.7.4 Yebio Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.7.5 Yebio Recent Development
11.8 Sanofi Pasteur SA
11.8.1 Sanofi Pasteur SA Company Details
11.8.2 Sanofi Pasteur SA Business Overview
11.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Introduction
11.8.4 Sanofi Pasteur SA Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.8.5 Sanofi Pasteur SA Recent Development
11.9 Virbac
11.9.1 Virbac Company Details
11.9.2 Virbac Business Overview
11.9.3 Virbac Gene Engineered Subunit Vaccine Introduction
11.9.4 Virbac Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.9.5 Virbac Recent Development
11.10 Pfizer Inc.
11.10.1 Pfizer Inc. Company Details
11.10.2 Pfizer Inc. Business Overview
11.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Introduction
11.10.4 Pfizer Inc. Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.10.5 Pfizer Inc. Recent Development
11.11 Walvax Biotechnology
11.11.1 Walvax Biotechnology Company Details
11.11.2 Walvax Biotechnology Business Overview
11.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Introduction
11.11.4 Walvax Biotechnology Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.11.5 Walvax Biotechnology Recent Development
11.12 Kontec
11.12.1 Kontec Company Details
11.12.2 Kontec Business Overview
11.12.3 Kontec Gene Engineered Subunit Vaccine Introduction
11.12.4 Kontec Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.12.5 Kontec Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Engineered Subunit Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Therapeutic Gene Engineered Subunit Vaccine
1.2.3 Preventative Gene Engineered Subunit Vaccine
1.3 Market by Application
1.3.1 Global Gene Engineered Subunit Vaccine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Human Use
1.3.3 Veterinary Use
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Gene Engineered Subunit Vaccine Market Perspective (2016-2027)
2.2 Gene Engineered Subunit Vaccine Growth Trends by Regions
2.2.1 Gene Engineered Subunit Vaccine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Gene Engineered Subunit Vaccine Historic Market Share by Regions (2016-2021)
2.2.3 Gene Engineered Subunit Vaccine Forecasted Market Size by Regions (2022-2027)
2.3 Gene Engineered Subunit Vaccine Industry Dynamic
2.3.1 Gene Engineered Subunit Vaccine Market Trends
2.3.2 Gene Engineered Subunit Vaccine Market Drivers
2.3.3 Gene Engineered Subunit Vaccine Market Challenges
2.3.4 Gene Engineered Subunit Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Engineered Subunit Vaccine Players by Revenue
3.1.1 Global Top Gene Engineered Subunit Vaccine Players by Revenue (2016-2021)
3.1.2 Global Gene Engineered Subunit Vaccine Revenue Market Share by Players (2016-2021)
3.2 Global Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Gene Engineered Subunit Vaccine Revenue
3.4 Global Gene Engineered Subunit Vaccine Market Concentration Ratio
3.4.1 Global Gene Engineered Subunit Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Engineered Subunit Vaccine Revenue in 2020
3.5 Gene Engineered Subunit Vaccine Key Players Head office and Area Served
3.6 Key Players Gene Engineered Subunit Vaccine Product Solution and Service
3.7 Date of Enter into Gene Engineered Subunit Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Engineered Subunit Vaccine Breakdown Data by Type
4.1 Global Gene Engineered Subunit Vaccine Historic Market Size by Type (2016-2021)
4.2 Global Gene Engineered Subunit Vaccine Forecasted Market Size by Type (2022-2027)
5 Gene Engineered Subunit Vaccine Breakdown Data by Application
5.1 Global Gene Engineered Subunit Vaccine Historic Market Size by Application (2016-2021)
5.2 Global Gene Engineered Subunit Vaccine Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Gene Engineered Subunit Vaccine Market Size (2016-2027)
6.2 North America Gene Engineered Subunit Vaccine Market Size by Type
6.2.1 North America Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
6.2.2 North America Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
6.2.3 North America Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
6.3 North America Gene Engineered Subunit Vaccine Market Size by Application
6.3.1 North America Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
6.3.2 North America Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
6.3.3 North America Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
6.4 North America Gene Engineered Subunit Vaccine Market Size by Country
6.4.1 North America Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
6.4.2 North America Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Gene Engineered Subunit Vaccine Market Size (2016-2027)
7.2 Europe Gene Engineered Subunit Vaccine Market Size by Type
7.2.1 Europe Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
7.2.2 Europe Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
7.2.3 Europe Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
7.3 Europe Gene Engineered Subunit Vaccine Market Size by Application
7.3.1 Europe Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
7.3.2 Europe Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
7.3.3 Europe Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
7.4 Europe Gene Engineered Subunit Vaccine Market Size by Country
7.4.1 Europe Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
7.4.2 Europe Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size (2016-2027)
8.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type
8.2.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
8.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application
8.3.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
8.4 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region
8.4.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Gene Engineered Subunit Vaccine Market Size (2016-2027)
9.2 Latin America Gene Engineered Subunit Vaccine Market Size by Type
9.2.1 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
9.2.2 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
9.2.3 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
9.3 Latin America Gene Engineered Subunit Vaccine Market Size by Application
9.3.1 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
9.3.2 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
9.3.3 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
9.4 Latin America Gene Engineered Subunit Vaccine Market Size by Country
9.4.1 Latin America Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
9.4.2 Latin America Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size (2016-2027)
10.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type
10.2.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
10.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application
10.3.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
10.4 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country
10.4.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Gene Engineered Subunit Vaccine Introduction
11.1.4 Merck Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.1.5 Merck Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Gene Engineered Subunit Vaccine Introduction
11.2.4 GSK Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.2.5 GSK Recent Development
11.3 Tiantan
11.3.1 Tiantan Company Details
11.3.2 Tiantan Business Overview
11.3.3 Tiantan Gene Engineered Subunit Vaccine Introduction
11.3.4 Tiantan Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.3.5 Tiantan Recent Development
11.4 Pulike
11.4.1 Pulike Company Details
11.4.2 Pulike Business Overview
11.4.3 Pulike Gene Engineered Subunit Vaccine Introduction
11.4.4 Pulike Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.4.5 Pulike Recent Development
11.5 Greffex
11.5.1 Greffex Company Details
11.5.2 Greffex Business Overview
11.5.3 Greffex Gene Engineered Subunit Vaccine Introduction
11.5.4 Greffex Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.5.5 Greffex Recent Development
11.6 CureVac
11.6.1 CureVac Company Details
11.6.2 CureVac Business Overview
11.6.3 CureVac Gene Engineered Subunit Vaccine Introduction
11.6.4 CureVac Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.6.5 CureVac Recent Development
11.7 Yebio
11.7.1 Yebio Company Details
11.7.2 Yebio Business Overview
11.7.3 Yebio Gene Engineered Subunit Vaccine Introduction
11.7.4 Yebio Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.7.5 Yebio Recent Development
11.8 Sanofi Pasteur SA
11.8.1 Sanofi Pasteur SA Company Details
11.8.2 Sanofi Pasteur SA Business Overview
11.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Introduction
11.8.4 Sanofi Pasteur SA Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.8.5 Sanofi Pasteur SA Recent Development
11.9 Virbac
11.9.1 Virbac Company Details
11.9.2 Virbac Business Overview
11.9.3 Virbac Gene Engineered Subunit Vaccine Introduction
11.9.4 Virbac Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.9.5 Virbac Recent Development
11.10 Pfizer Inc.
11.10.1 Pfizer Inc. Company Details
11.10.2 Pfizer Inc. Business Overview
11.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Introduction
11.10.4 Pfizer Inc. Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.10.5 Pfizer Inc. Recent Development
11.11 Walvax Biotechnology
11.11.1 Walvax Biotechnology Company Details
11.11.2 Walvax Biotechnology Business Overview
11.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Introduction
11.11.4 Walvax Biotechnology Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.11.5 Walvax Biotechnology Recent Development
11.12 Kontec
11.12.1 Kontec Company Details
11.12.2 Kontec Business Overview
11.12.3 Kontec Gene Engineered Subunit Vaccine Introduction
11.12.4 Kontec Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.12.5 Kontec Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
